42 patents
Utility
Compounds As Inhibitors of Axl
28 Dec 23
Joel Worley BEATTY, Corinne Nicole FOLEY, Balint GAL, Manjunath LAMANI, Manmohan Reddy LELETI, Dillon Harding MILES, Srinivas PALADUGU, Jay Patrick POWERS, Shiwei QU
Filed: 27 Jun 23
Utility
Crystalline Forms of a CD73 Inhibitor and Uses Thereof
30 Nov 23
Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein.
Andrew M. K. Pennell, Eric F. Connor, Stephen Edmund Gottschling, Jim Dimetrios Colomvakos, Mohammed Asadullah Khan
Filed: 7 Apr 23
Utility
Solid forms of a CD73 inhibitor and the use thereof
21 Nov 23
Solid forms of Compound I, which modulates the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compound and methods for preparing the solid forms, are described herein.
Jenna Leigh Jeffrey, Kenneth V. Lawson, Dillon Harding Miles
Filed: 12 Dec 19
Utility
Antibodies to TIGIT
21 Nov 23
The present disclosure provides antibodies that specifically bind to TIGIT.
Kelsey Sivick Gauthier, Nigel Pelham Clinton Walker, Xiaoning Zhao, John Lippincott
Filed: 1 Jun 21
Utility
Dosing with an Azolopyrimidine Compound
26 Oct 23
Joyson J. Karakunnel
Filed: 23 Mar 23
Utility
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
17 Oct 23
Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein.
Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
Filed: 8 Jun 22
Utility
Inhibitors of HIF-2ALPHA and Methods of Use Thereof
25 May 23
Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy FOURNIER, Balint GAL, Clayton HARDMAN, Artur Karenovich MAILYAN, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Dongdong LIU, Guillaume MATA, Masa PODUNAVAC, Jay Patrick POWERS, Brandon Reid ROSEN, Kai YU
Filed: 28 Oct 22
Utility
Crystalline forms of a CD73 inhibitor and uses thereof
16 May 23
Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein.
Andrew M. K. Pennell, Eric F. Connor, Stephen Edmund Gottschling, Jim Dimetrios Colomvakos, Mohammed Asadullah Khan
Filed: 16 Jun 21
Utility
Oral formulations of CD73 compounds
25 Apr 23
Kenneth Victor Lawson, Manmohan Reddy Leleti, Jay Patrick Powers
Filed: 5 Mar 21
Utility
Tetralin and Tetrahydroquinoline Compounds As Inhibitors of HIF-2ALPHA
26 Jan 23
Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein.
Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU
Filed: 8 Jun 22
Utility
2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE Compounds
26 Jan 23
Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein.
Joel Worley BEATTY, Samuel Lawrie DREW, Jeremy Thomas Andre FOURNIER, Jenna Leigh JEFFREY, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Artur Karenovich MAILYAN, Guillaume MATA, Dillon Harding MILES, Jay Patrick POWERS, Ehesan UI SHARIF, Rhiannon THOMAS-TRAN, Xuelei YAN
Filed: 3 Jun 20
Utility
Inhibitors of HIF-2ALPHA
26 Jan 23
Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein.
Joel Worley BEATTY, Samuel Lawrie DREW, Jeremy Thomas Andre FOURNIER, Tezcan GUNEY, Steven Donald JACOB, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL, Guillaume MATA, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Xuelei YAN
Filed: 3 Dec 20
Utility
Dosing with an azolopyrimidine compound
25 Oct 22
Joyson Karakunnel
Filed: 14 Feb 19
Utility
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α
9 Aug 22
Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein.
Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
Filed: 18 Mar 21
Utility
Treatment of Oncogene-driven Cancers
4 Aug 22
The present disclosure provides methods of treating a subject identified as having an oncogene driven cancer comprising administering to said subject an agent targeting the extracellular production of adenosine and/or an agent antagonizing the activation by adenosine of one of its receptors.
Joanne B.L. Tan, Akshata R. Udyavar, Stephen W. Young
Filed: 11 Mar 20
Utility
Processes for Preparing Aminopyrimidine Compounds
28 Jul 22
Provided herein are improved processes for preparing aminopyrimidine compounds of Formula (I).
Manmohan Reddy LELETI, Dillon Harding MILES, Brandon Reid ROSEN, Ehesan Ul SHARIF, Jay Patrick POWERS
Filed: 5 Jun 20
Utility
Azolopyrimidine for the Treatment of Cancer-related Disorders
12 May 22
Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein.
Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN
Filed: 22 Oct 21
Utility
Inhibitors of CD73-mediated immunosuppression
8 Mar 22
Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein.
Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Ehesan Ul Sharif
Filed: 17 Nov 17
Utility
Solid Forms of a CD73 Inhibitor and the Use Thereof
3 Mar 22
Solid forms of Compound I, which modulates the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compound and methods for preparing the solid forms, are described herein.
Jenna Leigh JEFFREY, Kenneth V. LAWSON, Dillon Harding MILES
Filed: 12 Dec 19
Utility
Antibodies to Tigit
3 Mar 22
The present disclosure provides antibodies that specifically bind to TIGIT.
Kelsey Sivick GAUTHIER, Nigel Pelham Clinton WALKER, Xiaoning ZHAO, John LIPPINCOTT
Filed: 1 Jun 21